How mRNA Works: The Molecule That Carries Genetic Instructions

Every living cell runs on proteins: enzymes that drive chemical reactions, structural materials that give cells their shape, signaling molecules that coordinate responses to the environment. All of these proteins are built according to instructions encoded in DNA. But DNA itself never leaves the cell nucleus. The molecule that carries instructions from DNA to the protein-building machinery is messenger RNA — mRNA — and understanding it unlocks a surprisingly large part of modern biology and medicine.

From DNA to Protein: The Central Pathway

1. The DNA double helix stores the master copy
   DNA consists of two complementary strands wound around each other, held together by base pairs: adenine with thymine, and cytosine with guanine. The sequence of these bases encodes genes — instructions for building specific proteins. The human genome contains roughly 20,000 protein-coding genes arranged across 23 pairs of chromosomes, all packed into a nucleus about six micrometers across.
2. Transcription copies a gene into mRNA
   When a cell needs a particular protein, an enzyme called RNA polymerase binds to the gene’s promoter region and unwinds a section of the double helix. It reads the template strand and assembles a complementary RNA strand using the same base-pairing rules, except RNA uses uracil instead of thymine. The result is a pre-mRNA transcript that mirrors the gene’s sequence. Before leaving the nucleus, the transcript is processed: non-coding sections called introns are spliced out, the coding sections (exons) are joined together, a protective cap is added to the front end, and a poly-A tail of repeated adenine bases is added to the back.
3. mRNA travels to the cytoplasm
   The processed mRNA exits through nuclear pore complexes — channels in the nuclear membrane — and enters the cytoplasm, where the protein-building machinery waits. This physical journey is the reason mRNA exists at all: it is the portable copy that can move while the master DNA stays locked away and protected.
4. Ribosomes read the mRNA in codons
   Ribosomes are molecular machines assembled from protein and ribosomal RNA. Each ribosome clamps onto an mRNA strand and reads it three bases at a time. Each three-base triplet is called a codon, and each codon specifies a particular amino acid (or a stop signal). Transfer RNA (tRNA) molecules, each carrying a specific amino acid and a matching anticodon, shuttle to the ribosome and deliver their amino acid when their anticodon pairs with the mRNA codon. The ribosome links incoming amino acids into a growing chain.
5. The protein chain folds into its functional shape
   As the amino acid chain grows, it begins folding spontaneously based on the chemical properties of its constituent amino acids. Proteins adopt highly specific three-dimensional shapes, and that shape determines their function. Chaperone proteins assist with folding for longer or more complex chains. When the ribosome reaches a stop codon, the finished chain is released. A single mRNA molecule can be read by multiple ribosomes simultaneously, producing many copies of the same protein in a short time.

Why mRNA Is Temporary by Design

Unlike DNA, mRNA is deliberately short-lived. Cells contain enzymes called ribonucleases that continuously degrade RNA molecules. A typical mRNA in a human cell survives anywhere from a few minutes to several hours before it is broken down. This instability is not a flaw; it gives cells fine-grained control over protein production. When conditions change, a cell can simply stop making more of a particular mRNA and let existing copies degrade, quickly adjusting its protein output. The same logic applies to synthetic mRNA medicines: once delivered and used, the molecule disappears without leaving any trace in the cell’s DNA.

mRNA as a Medicine Platform

The key insight behind mRNA therapeutics is that if you can deliver a synthetic mRNA into the right cells, you can instruct those cells to produce almost any protein you choose. The COVID-19 vaccines demonstrated this at global scale: the mRNA instructs muscle cells near the injection site to produce a viral spike protein, which the immune system then learns to recognize. But the platform extends well beyond vaccines.

In oncology, personalized cancer vaccines are constructed from mRNA encoding mutant proteins unique to a patient’s tumor, training the immune system to attack cancer cells while ignoring healthy tissue. Early clinical trials for melanoma and pancreatic cancer have shown promising results. For rare diseases caused by missing or non-functional proteins, mRNA therapy can instruct the liver or other target organs to produce the missing protein on a dosing schedule, avoiding the need for permanent gene editing. Researchers are also exploring mRNA approaches to heart failure and inflammatory conditions.